If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Historically, Japanese consumption of animal products primarily focused on seafood. Influenced by Buddhist precepts against killing (sesshō) and the Shinto reverence for rice cultivation, meat from mammals and birds was often considered impure (kegare) and rarely eaten. Although domesticated chickens arrived in Japan during the Yayoi period, imperial edicts, such as those by Emperor Tenmu and Emperor Shōmu, forbade the killing and eating of certain animals, including chickens, and eggs were likely avoided as well. During the Sengoku period and Edo period, contact with Europeans, particularly in Western Japan, introduced meat-eating habits and the consumption of eggs. Namban confectionery using eggs, such as castella and bōro, also arrived. An early dish resembling TKG, called Tamago meshi (玉子飯, egg rice), appears in the 1805 cookbook Shirōto Hōchō (素人包丁, Amateur Cooking). It involved pouring beaten egg over cooked rice and steaming it. In 1838, records from the Nabeshima clan (Onji Nikki) mention "Odonburi Namatamago" (御丼 生玉子, bowl of rice [with] raw egg) being served to guests. The first person known to have eaten TKG in its modern, raw form was Kishida Ginkō (1833–1905), a pioneering journalist, around 1877. He reportedly recommended the dish to others. According to a 1927 magazine article describing Ginkō's habits, he seasoned it with salt and chili pepper (bansho). Eggs were a luxury during the food shortages after World War II, but became widely affordable from the 1950s onwards. TKG then gained popularity for its taste and nutritional value.
These methods may be used repeatedly over large timespans to monitor changes in the environment. Camera traps have been found to be a useful tool for the detection and documentation of elusive species, nest predators and in the quantitative analysis of frugivory, seed dispersal and behaviour.
== NatB phenotypes == Studying the effect of mutations in the NAA20 gene and the NAA25 gene in human cells have shown similar cellular phenotypes, among others that downregulating NatB activity reduce the cytoskeleton stability by affecting the actin microfilaments and focal adhesion. By knocking out either the NAA20 or NAA25 gene, the same was observed in human cells as in yeast cells; reduction of actin microfibrils, as well as reduction of focal adhesions in the cell. The findings in this study also indicated that human NatB is more likely to acetylate MQ- protein N-termini at a higher rate than yeast NatB. Meaning that NatB is important for maintaining the structure and movement of the cell. NatB might also be linked to proteins involved in cellular growth, as knockdown of both NAA20 and NAA25 resulted in a decrease in cell proliferation. Knocking down either NAA20 or NAA25 however resulted in decrease in cell proliferation, more cell death or cells locked in the interphase stage (G0/G1), respectively. NatB has also been studied in mouse embryonic fibroblasts (MEFs) cells by knocking out the NAA20 gene, and as in human and yeast, cell proliferation decreased, as well as actin cytoskeleton and disorganization of and decrease in focal adhesion. DNA replication was also negatively affected, probably causing senescence in the cells.
In series 4, Eric is retired, wealthy but professionally adrift and estranged from his children, when Harper recruits him to co-found SternTao, a fund dedicated to shorting corrupt companies, with fintech firm Tender as their first major target. Eric liquidates his family office to finance the venture, and he and Harper clash over boundaries, with Harper accusing him of losing his edge and using the partnership to compensate for his failures as a father. Eric identifies Tender’s “satellite office” in Sunderland, prompting Harper’s investigation into the company’s laundering of African revenues. He later receives a secretly recorded video of himself with a prostitute named Dolly—planted by Tender—alongside a passport indicating she is 15 years old. Despite the blackmail, Eric appears on CNN opposite Whitney Halberstram to call for a new audit. He then abruptly dissolves SternTao and ends his partnership with Harper without explanation; Harper brands him a coward. The Tender short ultimately nets £110 million, but Eric does not answer when Harper calls to share the news. Yasmin later shows Harper the incriminating video, falsely claiming Dolly misrepresented her age and that Eric was attracted to the idea of sleeping with a teenager, further devastating Harper.
Sources: en.wikipedia.org
== Management == Medical management of VHF patients may require intensive supportive care. Antiviral therapy with intravenous ribavirin may be useful in Bunyaviridae and Arenaviridae infections (specifically Lassa fever, RVF, CCHF, and HFRS due to Old World Hantavirus infection) and can be used only under an experimental protocol as IND approved by the U.S. Food and Drug Administration (FDA). Interferon may be effective in Argentine or Bolivian hemorrhagic fevers (also available only as IND).
== Works cited == Dill, Marshall (1954). "The Christian Trade Unions During the Last Years of Imperial Germany and the First Months of the Weimar Republic". Review of Social Economy. 12 (2). Taylor & Francis, Ltd.: 89–109. doi:10.1080/00346765400000024. ISSN 0034-6764. JSTOR 29767502. Retrieved 25 March 2024. Grünthal, Günther (1968). Reichsschulgesetz und Zentrumspartei in der Weimarer Republik. Beiträge zur Geschichte des Parlamentarismus und der politischen Parteien (in German). Droste. ISBN 978-3-7700-5056-7. Retrieved 27 November 2024. Grünthal, Günther (1979). ""Zusammenschluß" oder "Evangelisches Zentrum"? Ein Beitrag zur Geschichte der Deutschen Zentrumspartei in der Weimarer Republik". In Pöls, Werner (ed.). Staat und Gesellschaft im politischen Wandel. Beiträge zur Geschichte der modernen Welt (in German). Stuttgart: Klett Cotta. pp. 301–330. ISBN 9783129119006. Mitchell, Maria (2012). "Confessional Conflict in German History". The Origins of Christian Democracy: Politics and Confession in Modern Germany. Social History, Popular Culture, And Politics In Germany. University of Michigan Press. ISBN 978-0-472-02854-2. Retrieved 27 November 2024. Schmidgall, Markus (2012). Die Revolution 1918/19 in Baden. Karlsruhe Institute of Technology. ISBN 9783866447271.
Blood coagulation: prothrombin (factor II), factors VII, IX, and X, and proteins C, S, and Z Bone metabolism: osteocalcin, matrix Gla protein (MGP), periostin, and Gla-rich protein. Vascular biology: Matrix Gla protein, growth arrest – specific protein 6 (Gas6) Unknown functions: proline-rich γ-carboxyglutamyl proteins 1 and 2, and transmembrane γ-carboxy glutamyl proteins 3 and 4.
Sources: en.wikipedia.org
=== Parasitic disease === Ivermectin has been researched in laboratory animals, as a potential treatment for trichinosis and trypanosomiasis. Ivermectin has also been tested on zebrafish infected with Pseudocapillaria tomentosa.
=== Water vascular system === The water vascular system of the starfish is a hydraulic system made up of a network of fluid-filled canals and is concerned with locomotion, adhesion, food manipulation and gas exchange. Water enters the system through the madreporite, a porous, often conspicuous, sieve-like ossicle on the aboral surface. It is linked through a calcareous-lined canal called the stone canal, to a ring canal around the mouth opening. A set of radial canals branch off from the ring canal; one radial canal runs along the ambulacral groove in each arm. There are short lateral canals branching off alternately to either side of the radial canal, each ending in an ampulla. These bulb-shaped organs are joined to tube feet (podia) on the exterior of the animal by short linking canals that pass through ossicles in the ambulacral groove. There are usually two rows of tube feet but in some species, the lateral canals are alternately long and short and there appear to be four rows. The interior of the whole canal system is lined with cilia. Water is pushed into the tube face when longitudinal muscles in the ampullae contract, and shut the valves in the lateral canals. This causes the tube feet to stretch and touch the substrate. Although the tube feet resemble suction cups in appearance, the gripping action is a function of adhesive chemicals rather than suction. Other chemicals and relaxation of the ampullae allow for release from the substrate. The tube feet latch on to surfaces and move in a wave, with one arm section attaching to the surface as another releases.
Committee on Energy and Commerce Subcommittee on Health Subcommittee on Communications & Technology Subcommittee on Commerce, Manufacturing and Trade Committee on Natural Resources Subcommittee on Water, Wildlife, and Fisheries Subcommittee on Energy & Mineral Resources
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.